210
Participants
Start Date
October 15, 2011
Primary Completion Date
August 8, 2016
Study Completion Date
August 12, 2019
oprozomib
Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
Mayo Clinic Scottsdale, Scottsdale
Pacific Cancer Care, Salinas
Colorado Blood Cancer Institute, Denver
Mayo Clinic, Jacksonville
Winship Cancer Institute, Emory University, Atlanta
Rush University Medical Center, Chicago
University of Chicago Medical Center, Chicago
University of Maryland, Greenebaum Cancer Center, Baltimore
Dana Farber Cancer Institute, Boston
Mass General Hospital, Boston
Virginia Piper Cancer Institute, Minneapolis
Mayo Clinic, Rochester
Washington University School of Medicine Division of Oncology, St Louis
John Theurer Cancer Center at Hackensack University, Hackensack
Hematology Oncology of Northern New Jersey, Morristown
New York Oncology Hematology, Albany
Mount Sinai Medical Center, New York
Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville
Columbia Basin Hematology and Oncology, Kennewick
Lead Sponsor
Amgen
INDUSTRY